TRT + GLP-1 Stack: What Happens When You Run Both

Why the combination exists.

The pattern is showing up more frequently in men’s health clinics: a patient on testosterone replacement therapy adds semaglutide or tirzepatide for weight management, or a patient starting a GLP-1 gets TRT prescribed alongside it to protect against lean mass loss. Some clinicians prescribe both intentionally. Others inherit the combination when patients arrive already on one and requesting the other.

The logic is straightforward. GLP-1 receptor agonists are the most effective pharmacological weight loss tools available — semaglutide produced a mean 14.9% body weight reduction in the STEP 1 trial.^[1] But roughly a quarter of that weight loss is lean mass, not fat. Testosterone, meanwhile, increases protein synthesis, promotes nitrogen retention, and supports muscle maintenance even in caloric deficit.^[2] The combination, in theory, gives you the fat loss of a GLP-1 with the muscle-sparing effect of exogenous testosterone.

That is the theory. No RCT has tested it. What follows is physiological reasoning based on what each compound does individually, extrapolated to the scenario where they operate simultaneously. This is an emerging clinical pattern, not an established standard of care. Everything in this article should be read through that filter.

The physiological interaction.

Testosterone replacement therapy, at physiological doses, produces a well-characterized set of effects: increased muscle protein synthesis, enhanced nitrogen retention, upregulated erythropoiesis (more red blood cells), and improved glycogen storage capacity. Bhasin et al. demonstrated in 1996 that supraphysiologic testosterone doses increase muscle size and strength even without exercise — and that the effect is additive with resistance training.^[2]

GLP-1 receptor agonists produce a different set: suppressed appetite via central and peripheral signaling, delayed gastric emptying, increased fat oxidation, improved insulin sensitivity, and reduced hepatic glucose output.^[1] Tirzepatide, which acts on both GLP-1 and GIP receptors, produced even greater weight loss in the SURMOUNT-1 trial — up to 22.5% of body weight at the highest dose.^[5]

Now put them together, at least conceptually. TRT tells your body to build. GLP-1 tells your body not to eat. You have an anabolic signal paired with a caloric environment that fights against anabolism. The tension between these two pharmacological directions is the entire management challenge of the stack. Every practical question — how much protein, how hard to train, which labs to monitor — flows from this fundamental contradiction.

The protein paradox.

This is the central conflict. Testosterone replacement therapy creates a metabolic environment where protein synthesis is upregulated. The Endocrine Society’s clinical practice guideline for testosterone therapy notes the importance of adequate nutrition to support the anabolic effects of treatment.^[4] In practice, most clinicians working with TRT patients recommend protein intakes of 1.6–2.0+ g/kg/day to take full advantage of the hormonal environment.

GLP-1 receptor agonists make eating that much protein nearly impossible on many days. The appetite suppression is most intense 24–48 hours post-injection. Nausea compounds the problem. Delayed gastric emptying means food sits longer, and protein-dense meals — chicken breast, steak, eggs — are often the hardest to tolerate. A person who needs 140–160 grams of protein per day may struggle to consume 70 on injection day.

The result: the compound that makes your body better at using protein is paired with a compound that makes consuming protein significantly harder. Based on what we know about each individually, this is the variable most likely to determine whether the stack produces recomposition or just weight loss with partial muscle preservation.

Working around the suppression

• •Liquid protein on high-suppression days. Whey isolate shakes, bone broth, collagen stirred into coffee. A 30g whey shake is 120–140 calories and goes down when solid food does not.
• •Weekly protein cycling. Accept lower intake on days 1–3 post-injection and compensate with higher intake on days 4–7 when appetite returns. Think in weekly totals, not daily targets.
• •Leucine-rich sources for maximum muscle protein synthesis per gram. Whey, eggs, and dairy deliver more anabolic stimulus per calorie than plant proteins or collagen.
• •Smaller, more frequent meals. Four meals of 35g protein is more tolerable and arguably more effective for MPS than two meals of 70g.

The training volume ceiling.

TRT enhances recovery between sessions. That is one of its primary training advantages — not more volume per session, but faster turnaround between them. A natural lifter who needs 72 hours between heavy squat sessions may need only 48 on TRT. That expanded recovery window tempts people into 5–6 training days per week.

GLP-1 pulls the ceiling down. You are in a caloric deficit, whether you intended one or not. Recovery is fueled by calories and protein, both of which are constrained. The enhanced recovery from testosterone may be partially or fully offset by the reduced fuel availability from the GLP-1. Based on the individual effects of each compound, the net recovery capacity is somewhere between “natural lifter in a deficit” and “TRT user eating at maintenance” — likely closer to the former.

Physiological reasoning suggests the sweet spot for the stack is 3–4 sessions per week, structured around compound movements that recruit the most muscle mass per exercise. The goal is to provide sufficient stimulus to preserve (or slowly build) lean mass without exceeding recovery capacity.

• •Compound movements over isolation. Squats, deadlifts, bench, rows, and overhead press. These deliver the strongest anti-catabolic signal per unit of recovery cost.
• •Moderate volume: 12–16 hard sets per muscle group per week, not 20+. The caloric environment does not support high-volume approaches.
• •Conservative progression. Smaller weight jumps, longer holds at a given load. Add 5 lbs instead of 10. Stay at a weight for an extra week before progressing.
• •Deload when GI side effects spike. If you just titrated up on your GLP-1 dose and the nausea is severe, that is not the week to push a new PR. Reduce volume by 40% and hold intensity.

Hematocrit on the stack.

Testosterone drives hematocrit up. That is a well-established effect — TRT stimulates erythropoiesis via increased erythropoietin and suppressed hepcidin. The TRAVERSE trial, the largest cardiovascular safety study of TRT to date, used hematocrit monitoring as a key safety parameter, with protocol-specified dose reductions when HCT exceeded 54%.^[3]

GLP-1 receptor agonists may attenuate the rise slightly — reduced caloric intake means less dietary iron, and weight loss can reduce circulating blood volume. But this is speculation, not demonstrated in any study. The net direction of hematocrit on the stack is still up. TRT’s erythropoietic drive is pharmacological and dose-dependent. Any attenuation from reduced food intake is incidental and unreliable.

If anything, monitoring should be more frequent on the stack, not less. Dehydration from GLP-1 GI side effects can artificially elevate HCT readings, making it harder to distinguish true polycythemia from transient hemoconcentration. Draw labs when well-hydrated, not during a bout of nausea or vomiting. Every three months for the first year is a reasonable minimum.

Combined nutrient depletions.

Each compound has its own depletion profile. TRT increases zinc utilization — zinc is consumed in testosterone metabolism and aromatization. GLP-1 receptor agonists reduce B12 absorption through delayed gastric emptying and decreased intrinsic factor exposure. Reduced caloric intake across the board means lower dietary intake of virtually every micronutrient.

Based on the individual depletion profiles, the expected combined picture is a broader deficiency pattern than either compound alone. Physiological reasoning suggests these are the highest-priority nutrients to monitor and potentially supplement:

• •Zinc: 25–50 mg/day. Consumed in testosterone metabolism. Discuss dosing with your physician, as excess zinc depletes copper.
• •Vitamin B12: monitor serum levels at each lab draw. Supplement if below range. Sublingual or injectable forms bypass the GI absorption issues that GLP-1s may exacerbate.
• •Vitamin D: test and supplement to maintain 40–60 ng/mL. Caloric restriction reduces dietary vitamin D intake. Deficiency impairs both testosterone function and immune response.
• •Magnesium glycinate: 200–400 mg/day. Depleted by both caloric restriction and the GI losses common on GLP-1s. Glycinate form is better tolerated than oxide in a GI-sensitive population.
• •Iron: test before supplementing. Check ferritin and TIBC. TRT drives demand for iron (erythropoiesis requires it), but GLP-1 reduces dietary iron intake. Do NOT supplement iron without bloodwork — excess iron is toxic and elevated ferritin has its own risks.

For compound-specific depletion details, see The 7 Nutrients Your Protocol Is Depleting.

The lab panel for the stack.

Running two prescription compounds means monitoring both. The lab panel below combines standard TRT monitoring with the metabolic markers affected by GLP-1 therapy. Draw testosterone at trough (immediately before your next injection). Fast for lipids and A1C. Hydrate well for 48 hours before any draw to avoid artifactual elevations.

SomaForge is built for exactly this scenario — tracking multiple compounds alongside labs, nutrition, and training in one place, because the interactions between protocols are where the risk lives.

Body composition expectations.

The best-case outcome on the stack, based on physiological reasoning, is recomposition — losing fat while gaining or maintaining muscle simultaneously. This is normally difficult for natural lifters outside of the novice window, but TRT creates an anabolic environment that makes it more achievable even in a caloric deficit. The GLP-1 drives the deficit. The testosterone, in theory, protects the lean mass.

Realistic expectations: fat loss with meaningful muscle preservation rather than the roughly 25% lean mass loss observed in GLP-1 trials where resistance training and protein intake were not controlled variables.^[1] The three levers that may reduce lean mass loss are TRT’s anabolic support, consistent resistance training, and adequate protein intake. Remove any one of those three, and the lean mass protection weakens.

Track with multiple metrics, not just the scale. The scale is the worst tool for evaluating a recomposition. If you are losing fat and gaining muscle, the scale may barely move while your body composition transforms.

• •DEXA scans quarterly if accessible. The gold standard for tracking fat mass vs. lean mass changes over time.
• •Waist circumference weekly. The single best low-tech proxy for visceral fat loss.
• •Strength maintenance or progression. If your lifts hold steady or improve while the scale drops, lean mass is likely being preserved.
• •Progress photos under consistent conditions. Same lighting, time of day, clothing. Your eyes catch what the scale misses.
• •Rate of loss: 0.5–1% of body weight per week. Faster than that and lean mass loss accelerates regardless of TRT support.

Recovery on the stack.

Two opposing forces. TRT enhances recovery capacity — faster muscle repair, improved sleep architecture, better nitrogen balance. GLP-1’s caloric deficit suppresses it — less fuel for tissue repair, reduced glycogen replenishment, and the general metabolic downregulation that comes with sustained energy restriction. The net effect, based on physiological reasoning, depends heavily on the depth of the deficit.

Heart rate variability may stay suppressed even when resting heart rate drops. HRV reflects autonomic nervous system balance, and caloric deficits tend to push the sympathetic nervous system into dominance regardless of hormonal status. RHR, meanwhile, may decrease as body weight drops and cardiovascular efficiency improves. The two metrics can move in opposite directions on the stack — do not read a dropping RHR as proof that recovery is fine if HRV is simultaneously depressed for more than five consecutive days.

Joint health is a specific concern. Training in a caloric deficit increases mechanical stress on connective tissue that is receiving less nutritional support for repair. GLP-1 GI side effects may reduce collagen precursor availability. Some clinicians report anecdotally that joint complaints increase in patients on the stack, though no study has examined this.

Sleep is a mixed variable. Weight loss reduces sleep apnea risk and may improve sleep quality. Testosterone, when dosed to physiological levels, can normalize sleep architecture. But GI distress from GLP-1s — especially early in titration or after dose increases — can fragment sleep through nausea, reflux, or middle-of-the-night discomfort. The net effect varies by individual and by phase of treatment.

Warning signals

• •Sustained HRV depression lasting more than 5 days. A day or two of low HRV is normal variation. Five consecutive days suggests your recovery debt is accumulating faster than you can repay it.
• •Grip strength decline. If you cannot maintain your usual grip on deadlifts or rows, systemic recovery is compromised. Grip is often the first thing to go.
• •Persistent joint pain, especially in shoulders, knees, or elbows. This is not the same as muscle soreness. Joint pain that does not resolve within 48 hours of a session is a signal to reduce volume or increase calories.
• •Mood and motivation collapse. Sustained caloric deficit plus training stress can tank neurotransmitter production. If you feel flat for more than a week, something needs to change — usually calories up or volume down.

References.